Moffitt's size, its singular focus on cancer, and its close interaction and outreach with academic partners and caregivers throughout the state, nation, and world all contribute to the rich, collegial, and collaborative environment required to perform outstanding cancer research and educate the next generation. Moffitt's five research programs, supported in part by the Cancer Center Support Grant (CCSG), consist of integrative teams of more than 140 faculty members working together to tackle the complexity of cancer. The five programs are:
Cancer Biology & Evolution (CBE) is a first-in-kind CCSG Program that emerged from systematic in-house collaborations of mathematicians, evolutionary biologists, and basic and clinical cancer researchers. Although these research teams investigate cancer via traditional means, they include mathematicians and theorists who integrate multi-scalar data through quantitative models founded on evolutionary first principles.
The Cancer Epidemiology (CE) Program contributes to reducing cases of cancer through research to identify risk factors across the cancer continuum comprising etiology, progression, and outcome, and the translation of that knowledge into successful prevention and early detection interventions.
The Chemical Biology and Molecular Medicine (CBMM) Program integrates chemical biology and systems biology technologies to develop new therapeutic approaches for the treatment of cancer.
The Health Outcomes and Behavior (HOB) Program contributes to the prevention, detection, and control of cancer through the study of health-related behaviors, health care practices, and health-related quality of life. Work toward this goal involves research across the disease spectrum – from prevention and detection through to survivorship or advanced disease.
The Immunology (IMM) Program defines the mechanisms by which tumors evade rejection by the immune system and develops strategies to thwart them. Key to the Program’s success is the close integration of IMM clinical, translational, and basic scientists that facilitates rapid progression of novel immunotherapies from the bench to bedside.